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ABSTRACT 
MSL-109 is a monoclonal antibody specific to the cytomegalovirus (CMV) glycoprotein H with high neutralizing 
capacity. In a prospective, randomized, double-blind study, allogeneic hematopoietic stem cell transplantation 
(HSCT) recipients with positive donor and/or recipient serology for CMV before transplantation received either 
60 mg/kg MSL-109 (n = 59), 15 mg/kg MSL-109 (n = 60), or placebo (n = 60) intravenously every 2 weeks from day 
-1 until day 84 after transplantation. CMV pp65 antigenemia, CMV-DNA load in plasma, and viremia by culture 
were tested weekly. Primary end points were development of pp65 antigenemia at any level and/or viremia for 
which ganciclovir was given. There was no statistically significant difference in CMV pp65 antigenemia or viremia 
among patients in the 60-rag group (pp65 antigenemia, 47%; viremia, 15%), the 15-mg group (52%; 23%), and the 
placebo group (45%; 17%). There was also no difference in maximum levels of pp65 antigenemia, time to clear- 
ance of pp65 antigenemia after start of ganciclovir, CMV disease, invasive bacterial and fungal infections, time to 
neutrophil and platelet engraftment, acute graft-versus-host disease, days of hospitalization, and overall survival 
rate among the 3 groups. However, a subgroup analysis of CMV-seronegative r cipients with a seropositive donor 
(D+/R-) showed a transiently improved survival rate by day 100 in MSL-109 recipients (mortality: 60-mg group, 
1/13; 15-mg group, 1/12; placebo group, 6/10 [P = .02 for 60-rag versus placebo groups; P = .08 for 15-mg versus 
placebo groups]); by the end of follow-up, the difference was no longer statistically significant. The improved sur- 
vival rate in D+/R- patients could not be attributed to a reduction in CMV disease; however, MSL-109 was associ- 
ated with improved platelet engraftment and less grade III to IV acute graft-versus-host disease in this subgroup. 
In a subgroup analysis of CMV-seropositive recipients of MSL-109 (D+/R+ and D-/R+), overall mortality was 
increased compared to that of the placebo group (P = .12 for the 60-mg versus placebo groups, P = .05 for the 
15-rag versus placebo groups, and P = .04 for the dose levels combined versus placebo). MSL-109 was well toler- 
ated and no immune response to the drug was observed. Thus, MSL-109 was safe but did not reduce CMV infec- 
tion in allogeneic HSCT recipients. The transient survival advantage seen early after transplantation in CMV 
D+/R- patients and the negative ffect on survival in seropositive patients remain unexplained. Thus, there is no 
evidence that MSL-109 is beneficial in CMV-seropositive HSCT recipients. 
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INTRODUCTION 
Cytomegalovirus (CMV) infection continues to cause 
significant morbidity and mortality after hematopoietic stem 
cell transplantation (HSCT) [1]. Ganciclovir is presently the 
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most commonly used drug in prevention strategies. Ganci- 
clovir-based strategies have led to a significant reduction of 
CMV-related morbidity as well as mortality in selected set- 
tings [2-5]. However, drug toxicity [6], requirement for 
close laboratory monitoring, daily dosing, and interference 
with the reconstitution of CMV-specific T-cell immunity, 
which may lead to a late-onset CMV disease [7,8], continue 
to be significant problems. 
The use of CMV-specific antibodies for the prevention 
of CMV infection and disease after HSCT has been debated 
for some time. Although there is some evidence that CMV- 
specific antibodies given prophylactically may prevent 
asymptomatic CMV infection in seronegative HSCT recipi- 
ents [9,10], CMV disease has not been significantly reduced 
in randomized trials [10]. One hypothesis for the failure to 
provide protection from disease has been that the neutraliz- 
ing capacity of the antibody preparation used in these stud- 
ies was not sufficient. Thus, a monoclonal antibody specific 
to CMV, with high neutralizing capacity, might be more 
effective in preventing CMV infection and disease. 
MSL-109 is a human immunoglobulin (Ig)Gl-~c mono- 
clonal antibody specific for the CMV glycoprotein H [I 1]. 
Glycoprotein H is an important target for neutralizing anti- 
bodies [12]. MSL-109 has shown high neutralizing activity 
in vitro against laboratory strains as well as against clinical 
isolates, and there was an enhancement of in vitro foscarnet- 
and ganciclovir-induced inhibition of CMV replication 
[13,14]. Preclinical and clinical studies have shown no toxic- 
ity or immunogenicity [15,16]. A recent report of MSL-109 
as adjuvant therapy for CMV retinitis in patients with MDS 
failed to show a benefit in outcome [17]. However, the con- 
cept of using antibodies for treatment or prevention has 
been more successful in transplant recipients. For example, 
adjunctive treatment with intravenous immunoglobulin or
CMV Ig has been shown to improve outcome in HSCT 
recipients with CMV pneumonia [18-20]. In addition, CMV 
Ig has been effective in reducing primary CMV infection in 
HSCT recipients when given prophylactically, although 
CMV disease was not reduced [10]. In liver transplant recip- 
ients, CMV Ig reduced the incidence of CMV-related com- 
plications [21]. Collectively, these data suggest hat the 
pathogenesis of CMV infection may be different depending 
on patient settings and that antibodies may be effective in 
prevention of CMV infection when given in high doses. 
Although the introduction of polymerase chain reaction 
(PCR)- and antigenemia-guided preemptive therapy has led 
to a major reduction of CMV disease arly after transplanta- 
tion [2,3,22], toxicity associated with ganciclovir and foscar- 
net remains a clinical problem [3,6]. Thus, a reduction of 
CMV infection and thereby the need for preemptive ther- 
apy would be a potential clinical advantage. 
The purpose of this study was to examine prospectively 
whether MSL-109 given every other week from day -1 
until day 84 after allogeneic HSCT reduces asymptomatic 
CMV infection. 
PATIENTS AND METHODS 
Patients 
The study was performed at 3 centers: Fred Hutchinson 
Cancer Research Center (FHCRC), Seattle, Washington; 
City of Hope National Medical Center (COH), Duarte, 
California; and Stanford University Medical Center 
(SUMC), Stanford, California. Inclusion criteria included 
age greater than 10 years; patient or donor positive 
CMV-antibody status before transplantation; absence of 
CMV infection before randomization ( egative blood cul- 
ture, antigenemia assay, and PCR test results); Karnofsky 
performance status >20%; and informed consent. Exclu- 
sion criteria included patients with a history of CMV- 
related organ disease within 6 months prior to or at 
the time of study entry; treatment with any rodent or 
chimeric monoclonal antibody preparation; and use of fos- 
carnet, ganciclovir, or high-dose acyclovir (>500 mg/m 2 
every 8 hours for more than 10 days) within 1 month prior 
to or during the study; use of immunostimulants o her than 
granulocyte/granulocyte-macrophage colony-stimulating 
factors (eg, interleukin-2, interferon o~) within 1 month 
prior to or during the study; and intravenous immunoglobu- 
lin administration f >500 mg/kg every 2 weeks prior to or 
during the study. 
Patients were randomized before day -1 using a separate 
randomization schedule for each study center. Both the 
study centers and the sponsor were blinded to study assign- 
ment. Stratification criteria included seropositive recipient 
versus seronegative recipient and marrow donor type 
(matched related versus matched unrelated versus mis- 
matched). The study was approved by the Institutional 
Review Board at all 3 institutions and informed consent was 
obtained prior to study. 
Virologic Surveillance and Preemptive Therapy 
Pretransplantation CMV serologies were performed by 
an enzyme-linked immunosorbent assay (ELISA) at FHCRC 
(Premier CMV IgG; Meridian Diagnostics, Cincinnati, 
OH); indirect immunofluorescence assay (Virgo; Hemagen 
Diagnostics Inc., Columbia, MD) at COH; and passive latex 
agglutination test (Becton Dickinson, Meylan, France) and 
microparticle nzyme immunoassay (LMX Systems, Abbot 
Laboratories, Abbot Park, IL) at SUMC. All patients were 
monitored weekly at a single institution (FHCRC) using the 
CMV pp65 antigenemia assay (slides were prepared at the 
study sites and shipped overnight to FHCRC) and both con- 
ventional and shell vial centrifugation cultures as described. 
Briefly, antigenemia testing was performed on slides pre- 
pared with 150,000 dextran-separated peripheral blood 
leukocytes (PBL) using paraformaldehyde fixation and 
immunofluorescence staining with a monoclonal antibody 
directed against pp65 (CMV Brite Kit; Biotest Diagnostic 
Corporation, Denville, NJ) [23]. At COH and SUMC, a day 
-35 diagnostic bronchoalveolar vage (BAL) was performed 
as described [24]. Quantitative results of antigenemia were 
reported as number of positive cells per slide (150,000 PBL). 
In addition, plasma and PBL were stored and tested in 
batches by a quantitative PCR for CMV DNA. Details of 
the assay have been described earlier. Briefly, the plasma was 
treated with proteinase K, heat inactivated, spun down, and 
10 btL supernatant was used in a PCR assay as described by 
Gallez-Hawkins et al. [25]. The detection of the PCR prod- 
uct was done in a 96-well plate by ELISA, and the optical 
density readings were correlated to an established standard 
curve for quantitation. 
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Table  I .  Patient Cha'racteris#cs * 
Characteristics 
Study Group 
60-rag MSL-109 (n = 59) 15-mg MSL-109 (n = 60) Placebo (n = 60) 
Mean age, y 41 38 38 
Sex, n 
Male 24 32 39 
Female 35 28 21 
CMV serostatus, n (%) 
Recipient+, donor+ 28 (47) 33 (55) 27 (45) 
Recipient+, donor-  18 (3 I) 15 (25) 23 (38) 
Recipient-, donor+ 13 (22) 12 (20) I 0 (I 7) 
Donor  status, n (%) 
Matched related 33 (56) 36 (60) 33 (55) 
Mismatched related 9 (15) 7 (12) 6 ( I 0) 
Matched unrelated 14 (24) 13 (22) 18 (30) 
Mismatched unrelated 3 (5) 4 (6) 3 (5) 
Karnowsky score at study entry, mean percentage 78 78 78 
*CMV indicates cytomegalovirus. 
Ganciclovir or foscarnet therapy was started when anti- 
genemia t any level, viremia by blood culture, or BAL posi- 
tivity by shell vial culture was detected and continued until 
day 100 (ganciclovir: 5 mg/kg twice a day for 7 days fol- 
lowed by 5 mg/kg per day on 6 days per week; foscarnet 
90 mg/kg twice a day for 7 days followed by 90 mg/kg per 
day on 6 days per week). When ganciclovir was initiated, 
virologic testing was continued only by the standard method 
at the respective site (ie, antigenemia testing at FHCRC and 
PCR testing of plasma t COH and SUMC). 
Study Drug Administration 
Drugs used in this study were 15 mg/kg MSL-109, 
60 mg/kg MSL-109 (both dissolved in lactated Ringers solu- 
tion), and matched placebo for MSL-109 (lactated Ringers 
solution). The first dose was administered by 15-minute 
intravenous infusion; if well tolerated, subsequent doses 
were given as bolus intravenous injections. Patients received 
a total of 7 intravenous doses of the study drug, each dose 
administered every 14 days beginning on day -1 and ending 
at day 84 after transplantation. 
Study End Points 
The primary end point was the development of CMV 
pp65 antigenemia or viremia by shell vial centrifugation 
cultures. Secondary end points included CMV viremia, 
CMV DNA in plasma and PBL, CMV disease, survival 
rate, use of preemptive therapy, maximum levels of anti- 
genemia, time to clearance of antigenemia, time to neu- 
trophil engraftment, ime to platelet engraftment, devel- 
opment of acute graft-versus-host disease (GVHD),  
invasive bacterial and fungal infections, and days of hospi- 
talization before day 100. Cause-of-death analysis was 
done retrospectively without knowledge of the randomiza- 
tion code. 
Adverse-Events Monitoring 
Patients were monitored prospectively for laboratory 
and clinical adverse events, including infusion-related 
events. To determine whether there was an immune 
response to the MSL-109 monoclonal antibody in the 
recipients, 5 mL of serum was collected prior to each infu- 
sion and on days 98, 180, 210, and 240. Human anti-MSL- 
109 antibodies were tested by ELISA performed at Protein 
Design Labs (Freemont, CA). Briefly, 96-well plates were 
coated with 200 ~tL of a 2-~tg/mL solution of MSL-109. 
After blocking, 160 gL MSL-109 conjugated to horseradish 
peroxidase and 40 gL of either diluted patient serum or ser- 
ial dilutions of mouse anti-MSL-109 were added to the 
wells for 60 minutes at room temperature. After washing 
the wells, 200 gL of chromagen solution (0-phenylene 
diamine dihydrochloride) was added to each well and 
absorbance at490 nm was determined. 
Definitions 
CMV infection was defined as detection of any pp65 
antigenemia or viremia as detected by conventional or 
shell vial centrifugation cultures. CMV disease was defined 
as demonstration by culture or histology of CMV in biop- 
sies from visceral sites or as CMV detected by culture, 
direct fluorescent antibody staining', or cytologic examina- 
tion of BAL where CMV is found in the presence of new 
or changing pulmonary infiltrates [3]. CMV retinitis was 
defined by ophthalmologic criteria. Graft failure was 
defined, in absence of other causes, as an absolute neu- 
trophil count of <500/(L and the presence of CMV in mar- 
row as detected by PCR assay and immunohistologic 
analysis [1]. Death was determined to be CMV-associated 
if death occurred within 6 weeks after diagnosis of CMV 
disease or if CMV was identified in autopsy specimens in 
conjunction with typical histologic hanges [3]. Acute and 
chronic GVHD were defined as described [26,27]. Invasive 
bacterial and fungal infections were defined using previ- 
ously described criteria [28]. Diagnoses of bacteremia nd 
fungemia required at least 1 positive blood culture result, 
and common contaminants (eg, non-JK corynebacteria) 
were disregarded [29]. Neutrophi l  engraftment was 
defined as an absolute neutrophil count of >500/mm 3.
Platelet engraftment was defined as a platelet count of 
3 >20,000/ram and 7 days without platelet transfusions. 
BB &MT 345 
M. Boeckb et al. 
Statistics 
The primary end point of this study was the development 
of pp65 antigenemia and/or viremia. Secondary end points 
were CMV disease, time to clearance of antigenemia after 
start of ganciclovir, survival rate, cause of death, days of hos- 
pitalization, use of ganciclovir, bacterial and fungal infections, 
and adverse vents. All data were analyzed by intent-to-treat 
criteria. Patients who were randomized and received at least 1 
dose of study drug were included in this analysis. Assuming 
an overall incidence rate of 60% pp65 antigenenfia in the 
placebo group, the trial was designed to detect a reduction 
from 60% to 30% with either dose of MSL-109 with 80% 
power at a .05 significance level. Survival curves were esti- 
mated using the Kaplan-Meier method. Cumulative inci- 
dence curves were estimated according to the methods 
described in Kalbfleisch and Prentice [30], treating death as a 
competing risk. The significance of differences between sur- 
vival rate and cumulative incidence curves was based on the 
likelihood-ratio statistic from proportional hazards regression 
models. Comparisons of frequencies among groups were by 
the chi-square method; comparisons of continuous variables 
were by Wilcoxon rank sum test. 
RESULTS 
Patients 
Patient characteristics are shown in Table 1. Patients 
were balanced among the groups. 
Time to Antigenemia, Viremia, and CMV DNA in 
Plasma 
The times to first detection of antigenenfia, viremia, and 
PCR positivity are shown in Figure 1. There was no difference 
in the time to first detection of CMV by any of the 3 methods. 
There was also no difference in the quantity of CMV pp65 
antigen detected at the onset or maximum level of antigene- 
mia (Figure 2) nor a difference among the 3 groups regarding 
the primary end point of the study, ie, either pp65 antigenemia 
or viremia by shell vial centrifugation cultures. 
In the subgroup of D+/R- transplant recipients, there 
was no significant difference in using culture or PCR assay 
to detect CMV antigenemia or CMV viremia. Three 
(23.1%) of 13 patients receiving 60 mg/kg MSL-109 had 
positive test results for CMV antigenemia, with maximum 
levels of 11, 1, and 1 positive cells per slide, compared to 
2 (16.7%) of 12 patients receiving 15 mg/kg MSL-109 with 
maximum antigenemia levels of I and 2 positive cells per 
slide and 1 (10%) of 10 patients receiving placebo with a 
maximum antigenemia level of 5 positive cells per slide. 
CMV viremia by culture was detected in 1 (7.7%) of 
13 recipients of 60 mg/kg MSL-109, none of 12 recipients 
of 15 mg/kg MSL-109, and 1 (10%) of 10 placebo recipi- 
ents. PCR results for detection of CMV DNA in plasma 
were positive in 2 (15.4%) of 13 patients who received 
60 mg/kg MSL-109 (maximum level 3.3 x 106 and 1.02 x 
106 copies CMV DNA per mL), in 1 (8.3%) of 12 patients 
who received 15 mg/kg MSL-109 (maximum level 4.7 x 103 
copies CMV DNA per mL), and in 2 (20%) of 10 patients 
who received placebo (maximum levels 4.7 x 103 and 9.4 x 
10 s copies CMV DNA per mL). PCR results for detection 
of CMV DNA in PBL were positive in 4 (30.8%) of 
13 patients in the 60-mg MSL-109 group, 1 (8.3%) of 12 in 
the 15-rag MSL-109 group, and 2 (20%) of i0 patients who 
received placebo. 
Among CMV-seropositive recipients, there was no dif- 
ference in the time to first antigenemia orviremia relative to 
donor CMV serostatus (data not shown). 
Time to Clearance of Antigenemia 
The duration of pp65 antigenemia after start of ganci- 
clovir was determined in a total of 62 patients at 1 site 
(FHCRC). There were no differences in the duration of 
pp65 antigenemia among the treatment arms (Figure 3). 
CMV Disease 
There was no statistically significant difference in the 
incidence of early and late onset of CMV disease among the 
groups. Before day 100, CMV disease occurred in 3.3% 
(60-mg MSL-109), 6.7% (15-mg MSL-109), and 3.4% 
(placebo) of patients (P not significant). By the end of fol- 
low-up, the incidence rates of CMV disease were 5%, 
13.3%, and 8.5%, respectively. All cases of CMV disease 
occurred in CMV-seropositive recipients, resulting in the 
following overall incidence rates: 4.3%, 8.3%, and 4.1%, 
respectively, before day 100, and 6.4%, 16.6%, and 10.0%, 
respectively, during the entire follow-up period (P not 
significant). CMV-related death (ie, 6-week mortality after 
diagnosis) was not different among the groups (data not 
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Figure I. Time to first pp65 antigenemia (panel A), cytomegalovirus DNA in plasma (panel B), and detection of viremia by shell vial or conven- 
tional tube cultures (panel C). 
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shown). The proportion of different manifestations of CMV 
disease (pneumonia versus nonpneumonia) did not seem to 
be different among the groups (data not shown). 
seronegative r cipients. Overall, there was more death due to 
neurologic diseases (60-rag group) and due to cardiovascular 
disease (15-rag roup) (Table 2). 
Surv iva l  
Overall, survival rate was not different among the groups 
(Figure 4). A subgroup analysis based on recipient serostatus 
revealed that, by day 100, survival rate of D+/R- recipients 
receiving 60 mg/kg MSL-109 was improved compared to 
that of placebo recipients (60 mg/kg versus placebo, P = .02; 
15 mg/kg MSL-109 versus placebo, P = .08) (Figure 4C); 
however, this difference disappeared with increased follow- 
up. In contrast, survival rate appeared to be worse in CMV- 
seropositive recipients who received MSL-109 compared to 
that of placebo recipients (60 mg/kg MSL-109 versus 
placebo, P = .12; 15 mg/kg MSL-109 versus placebo, P = .05; 
any MSL-109 versus placebo P = .04) (Figntre 4B). Causes of 
death are listed in Table 2. By day 100, among seronegative 
recipients there was 1 case of pulmonary aspergillosis in the 
60-rag MSL-109 group and 1 case of diffuse alveolar dam- 
age/idiopathic pneumonia syndrome in the 15-rag MSL-109 
group. In the placebo group, there were 6 deaths: 1 case each 
of GVHD, GVHD/alveolar hemorrhage, graft failure/liver 
failure, graft failure/pulmonary aspergillosis, venoocclusive 
disease, and cavernous inus infection/atrial fibrillation. 
There was no CMV-associated death in any of CMV- 
Adverse  Events  
MSL-109 was well tolerated. There were no infusion- 
related side effects. There was no statistically significant dif- 
ference in adverse vents between the 2 MSL-109 groups 
and placebo group for any of the events. Specifically, there 
was no difference in the proportion of patients who had ele- 
vations of total bilirubin to twice the baseline value at study 
entry (60-rag MSL-109 group: 42 [71.2%] of 59 patients; 
15-rag MSL-109 group: 31 [51.7%] of 60 patients; and 
placebo group: 34 [56.7%] of 60 patients); elevations of 
greater than 2.5 times baseline level of aspartate amino- 
transferase l vels (60-rag MSL-109 group: 5 [8.5%] of 
59 patients; 15-rag MSL-109 group: 7 [11.7%] of 60 patients; 
and placebo group: 3 [5.0%] of 60 patients); elevations of 
greater than 2.5 times baseline level of alkaline phosphatase 
levels (60-rag MSL-109 group: 5 [8.5%] of 59 patients; 15-mg 
MSL-109 group: 1 [1.7%] of 60 patients; and placebo 
group: 3 [5.0%] of 60 patients); or elevations of greater than 
1.5 times baseline serum creatinine l vels (60-rag MSL-109 
group: 5 [8.5%] of 59 patients; 15-rag MSL-109 group: 
3 [5.0%] of 60 patients; and placebo group: 3 [5.0%] of 
60 patients). Overall, 2% of patients experienced a severe 
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Figure 4. Survival in alI patients (panel A), CMV-seropositive recipients (panel B), and CMV D+/R- patients (panel C). 
adverse event considered related to treatment with MSL-  
109. No difference in the frequency in severe adverse vents 
was observed among study groups. Laboratory abnormali- 
ties also did not differ among any of the study groups. 
Immune Response  to  MSL-109 
Antibodies to MSL-109 in the recipients were measured 
serially after transplantation. There were no anti-MSL-109 
antibodies detectable in any of the patients. 
Other  End  Point:s 
There was no statistically significant difference in the 
number of hospitalization days, invasive bacterial infections, 
invasive fungal infections, acute GVHD,  the use of ganci- 
clovir, and neutrophil and platelet engraftments among the 
study groups (Table 3). 
A subgroup analysis of D+/R-  patients howed a signifi- 
cantly higher proportion of patients with platelet engraft- 
ment in the 60-mg MSL-109 group than in the placebo 
group (11 of 11 versus 4 of 9 patients, respectively; P = .003). 
Platelet engraftment in patients receiving 15 mg/kg MSL-  
109 versus platelet engrafunent in placebo recipients was not 
significantly different (7 of 10 versus 4 of 9 patients, respec- 
tively). A significantly lower incidence of acute grades II I  to 
IV  GVHD was found among pat ients  who received 
15 mg/kg MSL-109 compared to those who received placebo 
Table 2. Conditions Present at Death * 
Event 
Study Group 
60-mg MSL-109 15-rag MSL-109 Placebo 
R+ D+/R- All R+ D+/R- All R+ D+/R- All 
(n-- 46) (n= 13) (n = 59) (n--  48) (n = 12) (n = 60) (n = 50) (n= 10) (n = 60) 
Relapse of the underlying condition 8 (17) 3 (23) I I (19) 7 (15) 2 (17) 9 (15) 6 (12) 0 6 (10) 
Graft-versus-host disease 0 0 0 4 (8) 0 4 (7) I (2) 2 (20) 3 (5) 
Graft failure 0 0 0 0 0 0 0 I (10) I (2) 
Multi-organ failure, including 7 (I 5) 2 (I 5) 9 (15) 2 (4) 0 2 (3) 3 (6) 4 (40) 7 (I 2) 
septicemia (+ GVHD)I-  
Respiratory failure t 4 (9) 0 4 (7) 5 (10) I (8) 6 (10) 3 (6) 0 3 (5) 
Invasive fungal disease (_+ GVHD)  4 (9) I (8) 5 (8) 4 (8) 0 4 (7) 6 (12) I (10) 7 (12) 
Gastrointestinal complications I (2) 0 I (2) 7 (15) I (8) 8 (13) I (2) 0 I (2) 
(veno-occlusive disease, bleeding, 
ischemic colitis) (_+ GVHD)  
Viral disease (EBV-PTLD, RSV I (2) 0 I (2) I (2) 0 I (2) 3 (6) 0 3 (5) 
pneumonia, CMV disease) 
Coronary artery disease/cardiac death~ 0 0 0 I (2) 2 (I 7) 3 (5) 0 0 0 
Central nervous system disease of 3 (7) 0 3 (5) 0 0 0 0 0 0 
unclear etiologyw 
Total 28 (61) 6 (46) 34 (58) 31 (64) 6 (50) 37 (62) 23 (46) 8 (80) 31 (52) 
*Data are n (%). MSL-109 is a monoclonal antibody specific to the cytomegalovirus (CMV) glycoprotein H. D+, R+, or R- indicate donor or 
recipient CMV seropositivity or seronegativity; GVHD, graft-versus-host disease; EBV-PTLD, Epstein-Barr virus-induced posttransplantation 
Iymphoproliferative disorder; RSV, respiratory syncytial virus. 
1-No infectious etiology identified. 
~:P < .05 (chi-square t st). 
w the following conditions: brain abscess of unclear etiology (no biopsy/autopsy performed); progressive central nervous ystem infec- 
tion with ring-enhancing lesions of unclear etiology and unidentified puhnonary infiltrates (no biopsy/autopsy performed); and severe leukoen- 
cephalopathy (no biopsy/autopsy performed) (P < .05 by chi-square test). 
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(2 [16.7%] of 12 patients versus 6 [60%] of 10 patients, 
respectively; P = .04). The incidence of acute grade III to 1V 
GVHD in the 60-mg/kg roup (5 [38.5%] of 13 patients) was 
not significant. 
DISCUSSION 
This study shows that MSL-109, a human monoclonal 
IgG anti-CMV antibody, does not reduce the incidence of 
CMV infection in allogeneic HSCT recipients at high risk 
for CMV reactivation and primary infection. The antibody 
was well tolerated and did not induce an immune response. 
Overall, survival rate was not different among the groups. 
However, in the subgroup of CMV D+/R- transplant recipi- 
ents, a transient survival benefit was observed in MSL-109 
recipients, whereas CMV-seropositive patients who received 
MSL-109 had a higher mortality rate. 
MSL-109 has been used without success as adjuvant 
therapy for CMV retinitis in HIV-infected individuals [17]. 
This study was aimed at determining whether a high-titer 
CMV-specific human monoclonal antibody is effective in 
prevention of CMV infection. The drug was given prophy- 
lactically to HSCT recipients at risk for CMV infection to 
reduce the incidence of CMV infection and thereby the 
need for preemptive therapy after allogeneic HSCT. This 
study failed to demonstrate such an effect. CMV infection 
did not seem to be affected by the antibody when analyzed 
in a time-to-event analysis as well as in a quantitative fash- 
ion, using several different quantitative measurements such 
as pp65 antigenemia and quantitative PCR for CMV DNA 
in plasma or PBL. There also did not seem to be a differ- 
ence in the severity of CMV infection, as indicated by the 
similarity in the maximum level of antigenemia, the break- 
through rate of CMV disease, and the time to clearance of 
pp65 antigenemia. Other end points such as time to platelet 
and neutrophil engraftment, invasive bacterial and fungal 
infections, as welt as the development of acute GVHD, were 
also not statistically affected. When seropositive recipients 
and D+/R- recipients were analyzed separately, there was 
also no difference in CMV end points. 
Possible reasons for the apparent failure to prevent 
CMV infection include inadequate dosing, viral resistance, 
strain differences, or inmmne escape. It may not be too sur- 
prising for an antibody treatment to be ineffective in pre- 
venting CMV infection in seropositive recipients in whom 
CMV stems from reactivation of latent virus and is primar- 
ily control led by celt-mediated immune surveil lance 
[31,32]. Thus, in these patients, even higher doses may not 
be effective given the mechanism of immunologic ontrol. 
On the other hand, an important role of antibodies in con- 
trolling CMV reactivation i  seropositive HSCT recipients 
has been suggested in a recent study [33]. Finally, the possi- 
bility of immune escape must be considered as potential 
reason for lack of efficacy. The glycoprotein H epitope is an 
important arget for neutralizing antibodies [12,34]. How- 
ever, inefficient neutralization may occur due to strain dif- 
ferences and other currently unknown immune escape 
mechanisms [35]. 
The trend toward a survival disadvantage in CMV- 
seropositive MSL-109 recipients was unexpected (Figure 4B). 
Although the numbers were small and this was a subgroup 
analysis, a similar effect on overall survival was reported from 
a randomized trial of MSL-109 as adjuvant reatment for 
CMV retinitis in HIV-infected individuals [17]. A cause-of- 
death analysis did not provide insight into possible mecha- 
nisms, although there was a trend toward more deaths associ- 
ated with neurologic and cardiovascular disease in MSL-109 
recipients (Table 2). However, the mechanism for the associa- 
tion remains unexplained because the specific conditions 
present at death were quite diverse among these patients. 
The situation in D+/R- patients is different, however. 
An important role of neutralizing antibodies in primary 
Table 3. Seconda~ 7 End PoiTm-* 
Event 60-mg 
Study Group 
MSL- 109 (n = 59) 15-mg MSL- 109 (n = 60) Placebo (n = 60) 
Platelet engraftment (>2O,000/~tL, 7 days without platelet transfusion) 
Percentage of patients 79.6 
Median day (range) 22 (8-146) 
Neutrophil engraftment (ANC, >500/gL) 
Percentage of patients 98.2 
Median day (range) 21 (10-38) 
Patients treated with ganciclovir, n (%) 27 (45.8) 
Acute GVHD, grades Ill-IV, n (%) 18 (30.5) 
Other invasive infections by day 100, n (%) 
Any invasive bacterial or fungal infection 36 (61.0) 
Any bacterial infection 30 (50.9) 
Gram-positive bacteremia (except coagulase-negative staphylococci) 24 (40.7) 
Gram-negative bacteremia only 6 (I 0.2) 
Any invasive fungal infection I I (18.6) 
Mold infections only 7 (I 1.9) 
Yeast infections only 4 (6.7) 
Days of hospitalization, median days (range) 36 (22-89) 
76.4 81.8 
19 (8-111) 23(11-79) 
92.9 94.6 
18 (8-85) 21 (9-51) 
31 (51.7) 34 (56.7) 
i 5 (25.0) t 8 (30.0) 
38 (63.3) 30 (50.0) 
38 (63.3) 25 (41.7) 
35 (58.3) 18 (30.0) 
12 (20.0) 4 (6.7) 
16 (26.6) I I (I 8.3) 
8 (13.3) 6 (10.0) 
8 (13.3) 5 (8.3) 
42.5 (16-105) 38 (21-81) 
*There was no statistically significant difference for any of the clinical variables between the 3 groups. MSL-109 is a monoclonal ntibody spe- 
cific to the cytomegalovirus glycoprotein H.ANC indicates absolute neutrophil count; GVHD, graft-versus-host di ease. 
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infection has been documented in both animal and human 
models. For example, in a mouse CMV model, Rubin et al. 
demonstrated protect ion against lethal challenge with 
murine CMV [36]. Furthermore,  previous studies with 
CMV Ig in HSCT recipients have shown a reduction of 
CMV infection, but no effect on CMV disease and survival 
was observed [10]. Also, antibody preparations (polyclonal 
and monoclonal) against a different virus, ie, respiratory 
syncytial virus, have proven to be effective in preventing 
serious virus-associated complications [37]. Thus, the appar- 
ent lack of effect on CNfV infection in D+/R-  recipients was 
somewhat unexpected, although the sample size was proba- 
bly too small to make firm conclusions in these patients 
with regard to the prevention of primary CMV infection. 
Although there was no major effect on CMV infection in 
D+/R- patients, we did observe a transient survival benefit 
(up to 1.5 years) in patients who received high-dose MSL- 
109. Although this survival benefit could not be attributed 
to a reduction in CMV infection or disease, the finding is 
intriguing because it was observed in the patient population 
in which prophy lact ic  ant ibody  t reatment  might  be 
expected to work. The reason for the lack of a survival ben- 
efit in earlier studies using antibody-based prophylaxis may 
be due to the fact that the direct effects of CM~, ie, fatal 
pneumonia, may have obscured any other, more subtle 
effects of CMV that may have been affected by antibody 
treatment. Such indirect or immunomodulatory effects of 
CMV have been described in the solid organ transplanta- 
tion setting [21,38,39]. However, indirect effects of CMV 
have not been reported in HSCT to date, probably because 
in the past, most patients with CMV complications died. 
More recently, with the widespread use of preemptive 
antiviral therapy, CMV-related death has decreased ra- 
matically during the first 3 months after transplantation 
[2,8]. Thus, it is conceivable that primary CMV infection 
exerts indirect effects that predispose patients to nonviral 
infections, delayed platetet engraftment, or the severity of 
GVI-ID. These effects can become apparent only when 
direct CMV-related mortality is prevented with preemptive 
therapy strategies. A subgroup analysis of D+/R- recipients 
in this study suggested improved platelet engraftment and 
less severe acute GVHD. Thus, larger studies are needed to 
test whether MSL-109 is beneficial for D+/R-  patients. 
In conclusion, this study failed to show that MSL-109 
was effective in prevent ing CMV infect ion in CMV- 
seropositive and D+/R- HSCT recipients. The differential 
effect of MSL-109 on survival rate in seropositive recipients 
and D+/R- recipients was unexpected. It seems possible that 
prevention of primary infection may reduce indirect effects 
of CMV, such as a predisposition to bacterial or fungal 
infection, acute GVHD, or delayed platelct engraftment. A 
larger study of D+/R- patients is required to confirm these 
findings and to examine the underlying mechanisms of the 
survival benefit. 
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